dpp 4 inhibitors with glp 1 GLP-1 Series Part 1: Utilization drives decline in DPP-4 inhibitors, increase in SGLT2s among competitive drug classes Insight into Structure Activity Relationship

Some clinics offer pharmaceutical-grade oral versions, but clinical data is stronger on injections

For individuals seeking to lose weight safely, the most effective strategy remains a personalised, evidence-based programme that combines licensed medication (where appropriate), nutritional guidance, physical activity, behavioural support and regular clinical monitoring

The path to fertility care is further complicated by how doctors approach weight

Lilly USA LLC is the only United States company with FDA-approved products containing tirzepatide identified under the trade names Zepbound and Mounjaro Results based on a January 2026 analysis of 14,203 Noom GLP-1Rx Program members who actively logged weight over a 40-week period